- Maire Tecnimont's Unique Expertise in Process Engineering and Maintenance Services combine with AVEVA's competencies as A Digital Transformation Leader to Address Customer's Industrial Challenges
MILAN, May 4, 2021 /PRNewswire/ -- Maire Tecnimont Group, a leader in the global natural resource processing industry, through its subsidiary Tecnimont, its main Engineering, Procurement and Construction (EPC) contractor, has signed a Memorandum of Understanding (MoU) with AVEVA, a global leader in industrial software, driving digital transformation and sustainability, to create new digital predictive and prescriptive maintenance services that drive enhanced business outcomes.
This partnership will extend usage of AVEVA's Asset Performance Management (APM) solutions across the Maire Tecnimont Group, globally, enhancing plant operability and lowering maintenance costs. This will in turn deliver increased information availability empowering better, more informed decision-making, and ultimately improving overall business performance. As part of the agreement, the two companies will work together over a twelve-month period on a defined number of customer projects to promote the application of predictive maintenance technology for critical plant assets.
"Digital transformation is one of the technology drivers most needed to give our industry a much-needed boost. This MoU with AVEVA aligns seamlessly with Maire Tecnimont's strategy for digital transformation: it complements our value proposition which focuses on NextPlant, our new digital services and solutions portfolio that has been designed to fully meet customer's needs, while simultaneously improving our operational model through the creation of digital enablers," commented Pierroberto Folgiero, CEO, Maire Tecnimont Group.
"AVEVA's Asset Performance Management suite is well positioned to advance industrial operations of the future. By enabling companies to predict failures before they occur, we are helping to reduce unplanned downtime as well as drive efficiency and safety throughout plant operations. We are excited about the partnership with Maire Tecnimont and look forward to supporting our joint customers in overcoming today's industrial challenges by leveraging human experience with artificial intelligence," commented Kim Custeau, Vice President, Asset Performance Management, AVEVA.
As an EPC contractor and global leader in the transformation of natural resources, Maire Tecnimont will leverage its unique process, automation, and maintenance competencies to supply plant owners with perfectly customized digital products and solutions that are tailor-made for their maintenance needs. The combination of Maire Tecnimont's proven market experience and AVEVA's leadership as an industrial technology provider will deliver improved analytics which in turn will help to reduce inefficiencies, optimize operations, and improve our customer's profitability. With this MoU, Maire Tecnimont Group has reached a new milestone in its digital transformation journey, with the activation of a new technology-enabled value stream which is a crucial part of its roadmap. To achieve its drive to become the 'contractor of the future', Maire Tecnimont is enhancing overall value for plant owners through a suite of advanced digital products and services geared towards EPC customers.
Maire Tecnimont S.p.A.
Maire Tecnimont S.p.A., listed on the Milan Stock Exchange, heads an industrial group which leads the global natural resource conversion market (downstream oil & gas plant engineering, with technological and execution expertise). Its subsidiary NextChem operates in the field of green chemistry and technologies in support of the energy transition. The Maire Tecnimont Group operates in approx. 45 countries, though approx. 50 operative companies and about 9,000 people. For more information please see: www.mairetecnimont.com.
Group Media Relations firstname.lastname@example.org
CONTACT: Tommaso Verani, Tommaso.Verani@mairetecnimont.it, +39 366 6494966
HERZLIYA, Israel, May 10, 2021 /PRNewswire/ -- Nayax Ltd. ("Nayax") announced today the pricing of its global initial public offering of 63,500,000 ordinary shares at a price per share of ILS 10.50 (approx. USD 3.25). The offering comprises 44,000,000 ordinary shares by Nayax and an aggregate of 19,500,000 ordinary shares by three existing shareholders (the "Selling Shareholders"). In addition, Nayax has granted the underwriters a 30-day option to purchase up to an additional 9,525,000 ordinary shares from Nayax, at the initial public offering price. Nayax intends to use the net proceeds of approximately ILS 430 million (approximately USD 132 million) from the initial public offering for financing the expansion of Nayax's business activities, pursuing its strategy to enter new markets and financing acquisitions. Nayax will not receive any proceeds from the sale of ordinary shares by the Selling Shareholders. The offering is expected to close on May 12, 2021, subject to customary closing conditions.
Yair Nechmad, CEO, chairman and co-founder, stated: "We're excited to begin this new chapter in Nayax's journey and we believe it is only the beginning. We look forward to delivering value to our shareholders as we do to our growing number of customers across the globe every day. We're especially pleased to have completed a successful global offering on the Tel Aviv Stock Exchange. We hope it will pave the way for others to follow."
"This milestone was made possible by the hard work and dedication of our employees and business partners, to whom the board conveys its deep appreciation and gratitude. The IPO process had the full support and guidance of an outstanding team, including the investment bankers of Jefferies Group LLC, sole global coordinator, Oppenheimer & Co. Inc., lead international manager and Leader Capital Markets, lead Israeli manager, the lawyers at Herzog, Fox & Neeman, Davis Polk and Wardwell LLP, Gornitzky & Co. and Latham & Watkins, LLP, the auditors of PwC Israel and the Investor Relations experts of MS-IR LLC."
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
Nayax offers a complete cashless payment solution, telemetry, management suite and consumer engagement tools to retailers, including unattended retail. Nayax' features help operators improve their day-to-day operations and long-term planning and transforms unattended machines into 24/7 retail stores. Nayax also ensures all transactions are secure with EMV transactions and increase revenue by accepting all dominant payment options in each region. As a global company, Nayax's goal is to help their customers grow their business with their complete merchant account capabilities. Visit www.nayax.com for more information.
Visit www.nayax.com for more information.
The securities referred to in this announcement have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or under the securities laws of any state of the United States, and may not be offered, sold, resold or delivered, directly or indirectly, in or into the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. In the United States, any offer of the ordinary shares will be made only to "qualified institutional buyers" as defined in and in reliance on Rule 144A under the Securities Act or another available exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. Outside the United States, any offer will be made in accordance with Regulation S of the Securities Act.
Forward looking statement The information included in this press release contains, or may be deemed to contain, forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995 and the Israeli Securities Law, 1968). Said forward-looking statements, relating to the initial public offering, are subject to uncertainties and assumptions and the actual results may materially differ. All forward-looking statements in this press release are based on information available to Nayax on the date hereof. All written or oral forward-looking statements attributable to Nayax are expressly qualified in their entirety by the factors referred to above. Nayax does not intend to update these forward-looking statements.
IR Contact: Miri Segal MS-IR LLC email@example.com Tel: +1-917-6078654
REYKJAVIK, Iceland, May 10, 2021 /PRNewswire/ -- In a study published today, scientists at deCODE Genetics demonstrate for the first time how long-read DNA sequencing can be applied at population scale to unravel large structural variants that associate with human disease and other traits.
In a paper published today in Nature genetics, scientists at deCODE genetics, a subsidiary of the pharmaceutical company Amgen, have shown that long-read DNA sequencing can be applied at population scale to unravel large structural variants that associate with human disease and other traits. Up until now DNA sequence analysis has been performed using short-read sequencing, where the sequence examined is broken up into fragments that are no more than 151 base pairs. Using short-read sequencing scientists have been able to discern most small variations in the genome and population studies have allowed them to determine how they associate with diseases and other traits. However of 133,886 reliably genotyped structural variants detected with long-read sequencing only 60% can be detected with short-reads.
Using PromethION sequencers from Oxford Nanopore Technologies, researchers at deCODE genetics whole genome sequenced 3,622 Icelanders. DNA base pairs in the genome were sequenced on average at least 10 times, allowing for accurate characterization of all genomic variation within the individual. These variants were then imputed into a larger set of participants in various disease studies at deCODE genetics and associated with phenotypes. This has led to the discovery of several hitherto unknown associations of structural variants with diseases and other traits.
"This technology and algorithms we developed enable us to characterize almost all structural variants reliably and consistently on a population scale," says Bjarni V. Halldórsson, head of Sequence analysis, deCODE genetics.
The problem with short-read sequencing is that larger structural variants are difficult to discern directly. This is a major stumbling block in the attempt to fully understand the relationship between variation in the sequence of the human genome and human diversity. Due to their size, these large structural variants usually have greater impact than the smaller variants most commonly considered. Large structural variants frequently delete or insert whole genes or large parts of genes, making them particularly harmful.
"We are confident that the long-read sequencing applied at population level is going to help us to find much of the missing sequence diversity that we must have to fully understand how diversity in the sequence of the genome accounts for human diversity," says Kari Stefansson CEO and founder of deCODE genetics.
Based in Reykjavik, Iceland, deCODE is a global leader in analyzing and understanding the human genome. Using its unique expertise and population resources, deCODE has discovered genetic risk factors for dozens of common diseases. The purpose of understanding the genetics of disease is to use that information to create new means of diagnosing, treating and preventing disease. deCODE is a wholly-owned subsidiary of Amgen .
Contact: Thora Kristin Ásgeirsdóttir, PR and Communications, deCODE genetics, 00354 -570 1909, 00354 -894 1909
CATANIA, Italy, May 10, 2021 /PRNewswire/ -- SmartBug is an Italian startup that is getting ready to globally launch its home automation ecosystem on Kickstarter. SmartBug is a smart home system with which users can automate their home. A real revolution in the field of smart home and home automation: a disruptive alternative in the market that combines collaborative technology and personalized services in an elegant and smooth device. Without a hub, it offers a set of plugins with unlimited possibilities of use.
A touch and gesture enabled wall switch, designed for all of those who want to keep a minimalist and discreet design without giving up on technology. Just like in the theory of the "intelligent swarms," the SmartBugs installed around the home - while replacing the old wall switches - can collaborate among each other through a solution that integrates WiFi, Bluetooth, and IR depending on a decentralized system that shares a peer-to-peer strategy, beyond the modern cloud technology. The mesh network allows for a link between the various SmartBugs, creating a network that requires no signal repeaters. It's with the on-board IR Led that the receivers translate the light impulses into commands so as to allow the device to turn on the AC or change a channel on TV. With SmartBug, the user can control the most traditional technology through an intelligent app that can be downloaded on the smartphone where it stores all codes, adding infinite potentials. While a temperature and humidity sensor allows for the control of every environment and the HVAC. It can also interface with the weather stations on the web and prepare for the household needs.
With a high quality digital microphone and a buzzer, every SmartBug can manage the voice commands of all the smart home functions. Just like Amazon, Google and Apple's virtual assistants even in the absence of these latter. The listening feature can be activated and deactivated at will thus allowing to notice the presence of people, dangerous situations (cries for help) or suspicious noises (alarm feature).
SmartBug is also an intelligent ecosystem of control that allows one to save money by recognizing and managing the excessive loads of energy in a fast way and avoid triggering the circuit breaker. SmartBug can measure and control power usages, through the power meter or the power used by a single appliance through a monitoring dashboard that allows to determine the environmental footprint and the sustainable quality of life within someone's own home.
SmartBug will be launching its Kickstarter campaign by the end of May 2021, with the goal of introducing this smart home ecosystem to the global market.
SmartBug is a company that was registered in the Italian Chamber of Commerce (or board of trade) among the innovative startups. Founded at the end of 2019, SmartBug is a global fabless company whose primary goal is the development of new products and technologies for the rising markets. Capable of strong innovation, SmartBug wants to establish itself as the driving technology in the smart home market and in all the different technological areas of the home ecosystem. Among these we find mobile technologies with high energy sustainability, efficient home automation solutions and a large number of applications that revolve around the creation of smart environments, which adapt in an independent, proactive, and specific way to the needs and goals of the user to help him in his everyday life.
CONTACT: Media Relations: Paolo Magnano, CMO, firstname.lastname@example.org; Joy McKenna, Social Media Strategist, email@example.com; +38 095 792 8122 firstname.lastname@example.org
Web site: https://www.smartbug.it/
LIBERTYVILLE, Ill., 10 mei 2021 /PRNewswire/ -- Hollister Incorporated en KMT Medical vieren vandaag Founder´s Day, ter gelegenheid van de 100(e) verjaardag van hun moedermaatschappij, de onderneming John Dickinson Schneider Inc. (JDS Inc.). In het hoofdkantoor van Hollister Incorporated in Illinois vond een herdenkingsevenement plaats ter ere van de oprichter van JDS Inc., John Dickinson Schneider, en de rijke geschiedenis van het bedrijf, dat via livestream werd uitgezonden naar medewerkers over de hele wereld.
Op 10 mei 1921 richtte de 23-jarige John Dickinson Schneider JDS Inc. op met een drukpers in de kelder van het huis van zijn ouders in Chicago. In de daaropvolgende decennia leidde hij het bedrijf op basis van de onwrikbare principes van persoonlijke waardigheid, service en kwaliteit, terwijl hij het tegelijkertijd aanpaste en ontwikkelde tot de wereldwijde aanwezigheid van vandaag de dag op het gebied van medische producten en service. Tegen het einde van zijn carrière schonk hij zijn bedrijf, in een daad van grote vrijgevigheid, aan zijn werknemers als rentmeesters; en daarmee liet hij een nalatenschap na - een nalatenschap die niet beperkt blijft tot levenloze documenten, wettelijke kaders of versteende verhalen. De heer Schneider en zijn vrouw, Minnie Schneider, lieten een nalatenschap na die elke medewerker nog elke dag leeft.
"Vandaag markeert een speciaal moment in de tijd - een moment dat ons leven heeft beïnvloed en dat van miljoenen mensen over de hele wereld die afhankelijk zijn van onze producten en services om hun leven op een waardige manier te leiden", aldus V. George Maliekel, President en CEO, JDS Inc. "Onze bedrijfscultuur is de levende uitdrukking van de nalatenschap van de Schneiders. Onze cultuur bepaalt het karakter van ons bedrijf. Het leidt ons bij de beslissingen die we nemen, het werk dat we doen, de manieren waarop we met elkaar omgaan en hoe we onze klanten en de wereldwijde gemeenschap van dienst zijn".
JDS Inc. en de werkmaatschappijen van Hollister Incorporated en KMT Medical zullen het honderdjarig bestaan in 2021 blijven herdenken met wereldwijde activiteiten om medewerkers en klanten te inspireren door en te verbinden aan de erfenis van de Schneiders.
Over Hollister Incorporated Hollister Incorporated is een onafhankelijk bedrijf dat eigendom is van de werknemers en dat wereldwijd gezondheidszorgproducten ontwikkelt, produceert en op de markt brengt. De onderneming ontwikkelt en vervaardigt producten voor stomazorg, continentiezorg en kritieke zorg en ontwikkelt ook educatief ondersteuningsmateriaal voor patiënten en zorgverleners. Het hoofdkantoor is gevestigd in Libertyville, Illinois, heeft productie- en distributiecentra op drie continenten en verkoopt in bijna 80 landen. Hollister is een volledige dochteronderneming van de firma John Dickinson Schneider Inc. (JDS Inc.), een 100 jaar oud bedrijf. Hollister laat zich leiden door de gedeelde missie van JDS Inc. om het leven waardevoller en waardiger te maken voor mensen die gebruik maken van haar producten en diensten. www.Hollister.com.
Over KMT Medical Incorporated KMT Medical is een groep bedrijven die thuiszorgservices aan consumenten levert. In samenwerking met artsen streven de bedrijven ernaar klinische beslissingen te respecteren en tegelijkertijd producten van hoge kwaliteit, ongeëvenaarde expertise en gepersonaliseerde services te leveren. KMT Medical, aangekondigd in 2017, is een volledige dochteronderneming van de firma John Dickinson Schneider Inc. (JDS Inc.). KMT Medical-bedrijven laten zich leiden door een operationeel beleid dat in overeenstemming is met de missie en visie van het moederbedrijf, de firma John Dickinson Schneider, Inc. www.kmtmedical.com.
Media contact: Meredith Castro Bedrijfscommunicatie Meredith.Castro@hollister.com 224-358-7631
Web site: http://www.hollister.com/
- Manuscript highlights development of robust responses to both influenza and COVID-19 and protection against the SARS-CoV-2 virus
- Data shared via preprint server for biology, bioRxiv, ahead of publication
GAITHERSBURG, Md., May 10, 2021 /PRNewswire/ -- Novavax, Inc. , a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced data from a preclinical study of the company's combination quadrivalent seasonal flu vaccine (NanoFlu(TM)) and COVID-19 vaccine candidate (NVX-CoV2373). The NanoFlu/NVX-CoV2373 combination vaccine demonstrated positive immune responses to both influenza and SARS-CoV-2. A pre-print of the manuscript is available at bioRxiv.org.
The manuscript, titled 'Combination Respiratory Vaccine Containing Recombinant SARS-CoV-2 Spike and Quadrivalent Seasonal Influenza Hemagglutinin Nanoparticles with Matrix-M(TM) Adjuvant,' studied a combination vaccine comprising a quadrivalent nanoparticle influenza vaccine formulated together with a recombinant SARS-CoV-2 spike protein vaccine and Matrix-M(TM) adjuvant. The combination vaccine elicited robust responses to both influenza A and B and protected against the SARS-CoV-2 virus. Clinical studies of the combination vaccine are expected to begin by the end of the year.
"Despite low rates during the COVID-19 pandemic, influenza remains a significant risk to global public health and the need for versatile, more effective vaccines is as important as ever, including against the flu. This study's results build on our success to-date with NVX-CoV2373, and with NanoFlu, which successfully achieved all of its objectives in a pivotal Phase 3 trial announced last year," said Gregory M. Glenn, M.D., President of Research and Development, Novavax. "We believe that this novel combination vaccine candidate, which leverages Novavax' technology platform and Matrix-M(TM) adjuvant, could be an important future tool in the long-term fight against both of these harmful respiratory viruses."
The preclinical study found that the combination NanoFlu/NVX-CoV2373 (qNIV/CoV2373) vaccine induced functional influenza and COVID antibodies in ferrets. Hemagglutination inhibition (HAI) and ACE2 receptor-inhibiting titers were comparable between immunization with the combination vaccine and with its respective component vaccines. Antibody titers were elevated two weeks after a single dose and increased even further two weeks following a second immunization.
Hamsters that received the combination NanoFlu/NVX-CoV2373 vaccine had elevated levels of SARS-CoV-2 anti-S IgG two weeks after the first immunization, which increased significantly after a second dose, with levels comparable to animals that received the NVX-CoV2373 vaccine alone. Human ACE2 receptor inhibiting antibody levels responded similarly. The immune responses to influenza A and B strains elicited by NanoFlu/NVX-CoV2373 were comparable to immunization with NanoFlu alone. Further, the combination vaccine induced antibodies against SARS-CoV-2 neutralizing epitopes, including at hidden or cryptic sites, that are common between USA-WA1 and the B.1.351 variant.
Protection after SARS-CoV-2 challenge
When hamsters were challenged with SARS-CoV-2, animals immunized with NanoFlu/NVX-CoV2373 retained their body weight comparably to non-infected animals and those immunized with NVX-CoV2373 alone. An examination of viral load in the upper and lower respiratory tract showed that little or no virus was detected four days after COVID-19 infection in animals immunized with NanoFlu/NVX-CoV2373 or with just NVX-CoV2373. Microscopic and macroscopic observations of the lungs showed no remarkable findings in animals immunized with either the combination vaccine or with NVX-CoV2373 alone.
"Seasonal influenza and COVID-19 combination vaccines will likely be critical to combating emerging COVID-19 variants," said Russell 'Rip' Wilson, Executive Vice President and NanoFlu General Manager, Novavax. "Millions of people are affected by influenza each year in the U.S., and despite our vaccination efforts, currently available flu vaccines are only partially effective. Our NanoFlu vaccine Phase 3 clinical trial achieved all of its primary endpoints, and we expect this combination vaccine will help control both COVID-19 and influenza illness."
About NVX-CoV2373 NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic sequence of the first strain of SARS-CoV-2, the virus that causes COVID-19 disease. NVX-CoV2373 was created using Novavax' recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and is adjuvanted with Novavax' patented saponin-based Matrix-M(TM) to enhance the immune response and stimulate high levels of neutralizing antibodies. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19. In preclinical studies, NVX-CoV2373 induced antibodies that blocked the binding of spike protein to cellular receptors and provided protection from infection and disease. It was generally well-tolerated and elicited robust antibody response in Phase 1/2 clinical testing.
NVX-CoV2373 is being evaluated in two pivotal Phase 3 trials: a trial in the U.K. that demonstrated 100% protection against severe disease, efficacy of 96.4% against the original virus strain, 86.3% against the B.1.1.7/501Y.V1 variant and 89.7% overall; and the PREVENT-19 trial in the U.S. and Mexico that began in December 2020. It is also being tested in two ongoing Phase 2 studies that began in August 2020: A Phase 2b trial in South Africa that demonstrated 100% protection against severe disease and 48.6% efficacy against a newly emerging escape variant first described in South Africa, and a Phase 1/2 continuation in the U.S. and Australia.
NVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.
About Matrix-M(TM) Novavax' patented saponin-based Matrix-M(TM) adjuvant has demonstrated a potent and well-tolerated effect by stimulating the entry of antigen presenting cells into the injection site and enhancing antigen presentation in local lymph nodes, boosting immune response.
About NanoFlu(TM) NanoFlu(TM) is a recombinant hemagglutinin (HA) protein nanoparticle influenza vaccine produced by Novavax in its SF9 insect cell baculovirus system. NanoFlu uses HA amino acid protein sequences that are the same as the recommended wild-type circulating virus HA sequences. NanoFlu contains Novavax' patented saponin-based Matrix-M(TM) adjuvant.
About Novavax Novavax, Inc. is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu(TM), its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M(TM) adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.
Novavax Forward Looking Statements
Statements herein relating to the future of Novavax and the ongoing development of its vaccine and adjuvant products are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those identified under the heading "Risk Factors" in the Novavax Annual Report on Form 10-K for the year ended December 31, 2020, as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.
Investors Novavax, Inc. Erika Schultz | 240-268-2022 email@example.com
Solebury Trout Alexandra Roy | 617-221-9197 firstname.lastname@example.org
Novavax Media Amy Speak | 617-420-2461 Laura Keenan | 202-709-7521 email@example.com
Web site: http://www.novavax.com/
Bookings Open Today for All-Inclusive Resort Featuring 228 Suites, 40 Ultra-Luxe Villas with Private Pools and Expansive Restaurant and Entertainment Village
MIAMI, May 10, 2021 /PRNewswire/ -- Karisma Hotels & Resorts, the award-winning collection of properties spanning Latin America, the Caribbean and Mexico, and Margaritaville, the global lifestyle brand synonymous with fun and escapism, will open the doors to the new five-star Margaritaville(®) Island Reserve Cap Cana in October 2021. This will mark the second resort for the Island Reserve brand created in partnership with Karisma and Margaritaville - and the first in the Dominican Republic. The new build combines the amenities of a world-class, all-inclusive resort with Margaritaville's signature easy going lifestyle. Bookings open today with a grand opening rate starting at $209 per person per night.
"After launching the Island Reserve concept in Riviera Maya, we're thrilled to continue our partnership with Margaritaville to bring this lifestyle to the Dominican Republic in a way that really captures Cap Cana as a destination," said Mario Mathieu, Senior Vice President of Business Development, Design and Construction at Karisma Hotels & Resorts. "Cap Cana is the ideal setting for the newest addition to the portfolio, truly encompassing the carefree escapism that is central to the brand."
The partnership with Karisma has been a fruitful one for Margaritaville as it expands its footprint in the Caribbean.
"We are excited to introduce Margaritaville Island Reserve to Cap Cana in the Dominican Republic, one of the most stunning beaches in the world," said John Cohlan, CEO of Margaritaville. "Our expanding partnership with Karisma is all about delivering the ultimate island experience - relaxation, fun, exceptional dining, over-the-top service, and quality entertainment - all to be enjoyed in the Margaritaville state of mind."
A Stunning Seaside Setting for the Ultimate Wanderlust Margaritaville Island Reserve Cap Cana sits on stunning Playa Juanillo, which is world renowned for its miles of pristine white sand beaches, clear turquoise waters, and idyllic sunsets. Located just 15 minutes from the Punta Cana International Airport, Margaritaville Island Reserve Cap Cana will feature 228 suites and 40 villas designed with elements inspired by the destination's seaside surroundings to transport guests to paradise. The "no worries'' experience is complete with an incomparable level of service from the resort's local Island Ambassadors who will cater to guests' every need, as well as rooms outfitted with modern conveniences such as customized in-room refreshment centers with goodies from Joe Merchant and access to Karisma's Island Reserve Inclusive(®) 24-hour in-room dining.
Guests will have 13 luxury room types to choose from, including swim up and honeymoon suites as well as the signature villas. The Jimmy Buffett Suite offers stunning views of the Caribbean Sea from the top floor of the main guest building, complete with sprawling indoor and outdoor entertainment spaces including a 300-square-foot furnished terrace and a custom-built grill for private dining experiences.
The resort's upcoming opening is also expected to have a significant impact on the local tourism industry in the Dominican Republic, bringing much needed economic growth following the Covid-19 pandemic.
"It has been a privilege to work in partnership with Karisma Hotels & Resorts to bring the famed Margaritaville Island Reserve brand to life in Cap Cana," added Jesus Barderas, President of the Dominican-based Cobbo Bay Developers SA. "We look forward to witnessing the positive economic impact this resort will have on the local hospitality industry and the Dominican Republic as a whole."
Luxurious and Exclusive Villa Accommodations A signature element of the property is the 40 ultra-luxe Island Reserve villas where guests have exclusive access to a sprawling lagoon pool and an S.O.S. Swim Up Bar featuring hanging beds to relax in comfort. Offering the ultimate indulgence, each villa features a king-size bed, kitchenette, breakfast bar, living room, and expansive outdoor terrace offering either a private pool or direct access to the lagoon pool.
Expansive Entertainment and Nightlife in the Gourmet Village At the heart of the resort, the Gourmet Village will provide guests with the ultimate place to relax and have fun, featuring immersive music, entertainment, and unpretentious-yet-refined culinary and mixology offerings for a personalized vacation from start to finish.
The expansive destination features the Margaritaville Main Stage, an urban theater that will provide daily entertainment and tropical tunes to complement the vibrant seaside setting. Here, guests will also find dining options galore with seven of the resort's 10 food and beverage locations, from exquisitely prepared pastas at Frank & Lola's Italian Trattoria, to choice cuts at JWB Steakhouse and Pan Asian specialties at Mon So Wi.
Adjacent to the infinity pool will be the centrally located hotspot Rum Runners, where guests can mix, mingle, and enjoy an expertly crafted menu with nods to the Dominican Republic and West Indies' long history of producing some of the best rum in the world. The 5 o'Clock Somewhere Bar & Swim Up Bar, boasting views of Juanillo Beach, is the perfect place for a poolside cocktail, a cold beer, or margarita.
At Sports Hub, located in the Gourmet Village, guests can sign up for their favorite activities, from pickleball to tennis and aqua fitness classes. Those looking to indulge will enjoy 11,000-square-feet of rest and relaxation at St. Somewhere Spa, while the 2,200-square-foot Fins Up! Fitness Center will be open 24 hours for anyone who wants to re-energize, tone, or embark upon a new workout challenge. Little ones will also be kept engaged at Parakeet Kid's Club where a variety of fun, supervised daily activities await. Plus, the resort's premier Sky Wedding location, with stunning views from a private rooftop, will make for the ultimate romantic setting for exchanging vows.
Island Reserve Inclusive(®) Experience and Bookings Bookings open today with Island Reserve Inclusive rates covering all accommodations with tax, premium food & beverage offerings, 24-hour room service, Island Ambassador personal concierge service, and more. Grand opening rates start at $209 per person per night for bookings through June 15, 2021 for travel from October 1 through June 30, 2022.
To ensure a holistic approach to guest safety and wellness, Karisma Hotels & Resorts created a comprehensive well-being program called Karisma Peace of Mind [https://c212.net/c/link/?t=0&l=en&o=3156802-1&h=1295808810&u=https%3A%2F%2Fwww.karismahotels.com%2Fpeace-of-mind&a=Karisma+Peace+of+Mind](TM), which includes a free, on-site antigen test for guests traveling to the U.S. per CDC requirements.
For more information and to make a reservation, call your travel advisor or visit: www.margaritaville islandreserveresorts.com.
Renderings are available here.
About Karisma Hotels & Resorts Karisma Hotels & Resorts is an award-winning luxury hotel collection that owns and manages an impressive portfolio of properties in Latin America, the Caribbean and Europe. Property brands include Margaritaville Island Reserve by Karisma; El Dorado Spa Resorts by Karisma; Azul Beach Resorts by Karisma; Generations Resorts by Karisma; Karisma Villas; Allure Hotels by Karisma; Hidden Beach Resort by Karisma; Nickelodeon Hotels & Resorts; Sensatori Resorts; Sensimar Resorts; and Karisma Hotels Adriatic. Properties have been honored with the industry's top accolades including Conde Nast Traveler's "Top 100 Hotels in the World," Conde Nast Traveler's "Top 30 Hotels in Cancun," TripAdvisor(®) Traveler's Choice "Best Hotels for Romance," and AAA's "Five Diamond Award'' and "Four Diamond Award." Karisma Hotels & Resorts is committed to employee and community support while delivering authentic experiences to guests, receiving worldwide recognition for its compassionate and creative approach to hospitality management and product innovations.
About Margaritaville Margaritaville, a state of mind since 1977, is a global lifestyle brand inspired by Jimmy Buffett, whose songs evoke a passion for tropical escape and relaxation.
Margaritaville features over 20 lodging locations and over 20 additional projects in the pipeline, with nearly half under construction, two gaming properties and over 60 food and beverage venues including signature concepts such as Margaritaville Restaurant, the award-winning JWB Prime Steak and Seafood and 5 o'Clock Somewhere Bar & Grill. More than 20 million travelers every year change their latitude and attitude with a visit to a Margaritaville resort, residential real estate destination, vacation club, vacation home rental or restaurant. Consumers can also escape everyday through a collection of Margaritaville lifestyle products including apparel, footwear, frozen concoction makers, home décor, a satellite radio station and more.
To learn about Margaritaville's commitment to health, safety and sanitation, please visit us online: https://www.margaritaville.com/healthandsanitationcommitment.
CONTACT: Brynne Henry, MMGY NJF, firstname.lastname@example.org